


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

| | |
|-------------------|------------------------------|
| USAN (GH-70) | DIROCAFTOR |
| PRONUNCIATION | dye" roe kaf' tor |
| THERAPEUTIC CLAIM | Treatment of cystic fibrosis |

CHEMICAL NAMES

1. 3-Quinolinecarboxamide, 1,4-dihydro-*N*-[5-hydroxy-2,4-bis(trimethylsilyl)phenyl]-4-oxo-
2. *N*-[5-hydroxy-2,4-bis(trimethylsilyl)phenyl]-4-oxo-1,4-dihydroquinoline-3-carboxamide

STRUCTURAL FORMULA



| | |
|----------------------------|---|
| MOLECULAR FORMULA | C ₂₂ H ₂₈ N ₂ O ₃ Si ₂ |
| MOLECULAR WEIGHT | 424.65 |
| TRADEMARK | None as yet |
| SPONSOR | Proteostasis Therapeutics, Inc. |
| CODE DESIGNATIONS | PTI-808 |
| <u>CAS</u> REGISTRY NUMBER | 2137932-23-9 |
| UNII | 2G3T6M1AS9 |
| WHO NUMBER | 11355 |

gbk